Cited by 62Nanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsGastric Cancer Management and Outcomes

Nanoparticles guided drug delivery and imaging in gastric cancer

Nagaraju, Ganji Purnachandra, Srivani, Gowru, Dariya, Begum, Chalikonda, Gayathri, Farran, Batoul, Behera, Santosh Kumar, Alam, Afroz, Kamal, Mohammad Amjad·2021·Seminars in Cancer Biology

Abstract

Gastric cancer represents a deadly malignancy worldwide, yet current therapeutic regimens remain ineffective. Nanoparticle (NP) -based solutions could allow the design of novel therapeutic methods to eliminate this fatal disease. NPs typically carry out a significant role in multifunctional, multimodal imaging, and drug delivery carriers. In the recent decade, they have emerged as candidate approaches for the design of novel treatment strategies. Tumor nanotherapeutics characteristically possess various distinct advantages compared to conventional anti-cancer medications, which suffer from nonspecific bio-distribution, low solubility, and poor bioavailability. In this review, we will discuss the application of NPs in diagnosis and controlled drug delivery in gastric cancer (GC). We will focus on various NPs-based strategies employed against GC.

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2020.01.006

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The efficacy of repurposed therapeutic agents is chiefly determined by their side effects and resistance profiles.

    “The efficacy of repurposed therapeutic agents is chiefly determined by their side effects and resistance profiles.345”

    From Drug repurposing for cancer therapy (2024) · cites this paper as [345]

Cites

Flagged first, then by citations

4 of the 90 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Nagaraju, G. P., Srivani, G., Dariya, B., Chalikonda, G., Farran, B., Behera, S. K., Alam, A., & Kamal, M. A.
Affiliations
  • Emory University (US)
  • Banasthali University (IN)
  • Indian Council of Medical Research (IN)
  • King Abdulaziz University (SA)
Corresponding author
  • Nagaraju, Ganji Purnachandra
  • Kamal, Mohammad Amjad
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2021-02
Volume
69
Pages
69-76
ISSN
1044-579X (ISSN-L)
OpenAlex
W2999336257
Cited by
62
References
90
Citations by year
2026: 6 · 2025: 8 · 2024: 18 · 2023: 11 · 2022: 8 · 2021: 5 · 2020: 6
FWCI
0.50
Type
journal article
Language
en
Open access
closed
Locations
  • Seminars in Cancer Biology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Gastric Cancer Management and Outcomes
Keywords
gastric cancer, nanoparticles, targeted drug delivery, multimodal imaging, nanomedicine, controlled drug release, cancer diagnosis, bioavailability
MeSH terms
Animals, Antineoplastic Agents, Biological Availability, Humans, Stomach Neoplasms, Drug Delivery Systems, Nanoparticles, Multimodal Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review